检索结果-南通市图书馆

Final Results of a Phase II Study of Bevacizumab, Cisplatin and Pemetrexed as First-Line Therapy for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

引用

Journal of Cancer Therapy 2016年第7期7卷 455-463页

作者： Guillermo López Vivanco eider azkona Sergio Carrera Aintzane Sancho Itziar Rubio Juan Manuel Mañé Begoña Calvo Unai Aresti Aitziber Buque Inés Marrodán Alberto Muñoz Servicio de Oncología Médica Hospital de Cruces Bilbao Spain

Background: Efficacy and safety data for cisplatin and pemetrexed plus bevacizumabinnon squamousnon non-small cell lung cancer (NSCLC) are still limited. Nevertheless, either bevacizumab plus platinum doublet or pemetrexed plus platinum is approved options for first line therapy. Predictive factors for bevacizumab are needed. KRAS is one of the most common oncogenic drivers in lung cancer. Its prognostic and predictive value in NSCLC is under investigation. Patients and methods: This trial evaluates the addition of bevacizumab 7.5 mg/kg to cisplatin 75 mg/m2 plus pemetrexed 500 mg/m2 as first line treatment in stage IV non-squamous NSCLC patients. Maintenance bevacizumab was received as monotherapy until progressive disease, unacceptable toxicityor consent with drawal. The primary objective was progression free survival (PFS). Secondary objectives included overall survival (OS), safety, global objective responses and the determination of KRAS mutation at baseline. Results: From March 2009 to March 2012, 31 patients were enrolled. Mean age was 59.19 (standard deviation (SD) 8.53). From all the patients included in this trial, 67.70% were men. KRAS was wild type in 19 patients (58.06%);in 7 (22.58%) was mutated and was unknown in 6 patients (19.35%). Median PFS for KRAS mutated patients was 4 months, whereas for the KRAS wild type it was 7.9 months (P = 0.0031). Median OS was 4 months for the KRAS population, and 16.1 months for the KRAS wild type (P = 0.0032). Twenty four patients (77.42%) experienced at least a grade 3 - 4 adverse event. The most common grade 3 - 4 toxicity was asthenia. Conclusions: Both PFS and OS were statistically longer for the KRAS wild type patients compared with the KRAS mutated population (P = 0.0031). Median OS was shorter than the reported in previous trials with bevacizumab. Nevertheless, focussing on the OS for KRAS wild type patients, this achieves a result or 16.1 months. Therefore, this would be a consistent dat

关键词： Non-Small-Cell Lung Cancer Bevacizumab Pemetrexed Predictive Biomarker KRAS

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Evolution of laparoscopic gastrectomy for cancer in the East and West

引用

Chinese Journal of Cancer Research 2022年第6期34卷 579-586页

作者： eider Talavera-Urquijo Bas P.L.Wijnhoven Department of Surgery University Hospital of DonostiaDonostia-San Sebastian 20014Spain Department of Surgery Erasmus University Medical Centre RotterdamRotterdam 3000the Netherlands

Laparoscopic gastrectomy has evolved differently in Eastern and Western ***,safety and oncological outcomes of laparoscopic gastrectomy were addressed step-by-step by several randomized controlled trials from the *** phase III studies were published from the West that largely did not show a difference between the laparoscopic and open *** this,laparoscopic gastrectomy is seen as the standard for the surgical treatment of early and advanced gastric cancer in many European ***,we review and comment on some important studies on laparoscopic gastrectomy for gastric cancer from Eastern and Western countries and also comment on current and future challenges.

关键词： Laparoscopic gastrectomy minimally invasive surgery gastric cancer

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

The mechanisms of the relationship between glucocorticoids and cardiovascular diseases

引用

Chinese Medical Journal 2010年第23期123卷 3504-3504页

作者： eider Kardesoglu Zafer Isilak Omer Uz Turgay Celik Department of Cardiology Haydarpasa Training Hospital GulhaneMilitary Medical Academy Istanbul Turkey

To the editor： We have enjoyed reading an original article by Ji et al,1 entitled Influence of drug treatment on glucocorticoid receptor levels in patients with coronary heart disease, published in a recent issue of the Chinese Medical Journal. Herein, 80 patients with coronary artery disease were divided into four groups according to given drugs, and glucocorticoid （GC） receptor protein levels in peripheral blood lymphocytes were investigated before and I month after treatment in each group. In groups receiving beta blocker and nifedipine, increased levels were observed. They proposed that these increased levels might account for antiinflammatory effects of these drugs.

关键词： cardiovascular diseases levels antiinflammatory effects glucocorticoid receptor coronary artery disease coronary heart disease drug treatment peripheral blood nifedipine Influence reading Medical Chinese account four beta

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

缺锌对大鼠生长发育的影响

引用

中华医学杂志 1995年第4期75卷 230-232页

作者：赵霖 eider.,U 中国人民解放军总医院临床基础医学研究所

为了验证锌对婴幼儿生长发育的影响，用不同含锌量的人工半合成词料，饲养生长中的大鼠。对其生长、发育过程进行了详细的观察。结果锌严重缺乏组大鼠平均摄食总量仅为对照组的４３％左右，不同程度缺锌组大鼠平均体重增加量与饲料含锌... 详细信息

为了验证锌对婴幼儿生长发育的影响，用不同含锌量的人工半合成词料，饲养生长中的大鼠。对其生长、发育过程进行了详细的观察。结果锌严重缺乏组大鼠平均摄食总量仅为对照组的４３％左右，不同程度缺锌组大鼠平均体重增加量与饲料含锌量间呈显著正相关（ｒ＝０．９９６），严重缺锌组食物转化率为３．１９７，补锌的营养生理作用是显著提高了大鼠的食物利用率，但饲料含锌量提高２５倍，其食物转化率的改变却非常小。结合多项血液学及有关生化参数的分析测试结果，讨论了锌缺乏对大鼠生长的影响和缺锌诊断的综合评价方法。

关键词：生长障碍微量元素锌大鼠锌缺乏

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：